http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RO-135360-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b3aa294336d1b2a35ab1a41a5cd060c |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-215 |
| filingDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08df28b91ab4d3556b2c368f68d1692f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5d23b7b7a5fdaf85328e959114a5366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89efc224f146adf8aa81af25d857e24f |
| publicationDate | 2021-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RO-135360-A2 |
| titleOfInvention | RECOMBINED PLASMIDIAL DNA-BASED NANOPARTICLE SYSTEM FOR PROPHYLAXIS OF SARS-VOC-2 CORONAVIRUS INFECTION |
| abstract | The invention relates to a system of nanoparticles based on recombinant plasmid DNA (pDNA) for immunization against SARS-VOC-2 coronavirus infection. The system according to the invention consists of recombinant pDNA nanoparticles with a consensus sequence for spike viral antigen, and reporter genes for preclinical evaluation on cell cultures and in vivo models. The pDNA molecules are complexed with biocompatible cationic adjuvants such as Vaxfectin, Chitosan and Mannosylated Protamine for administration to the nasal mucosa and pulmonary epithelium in experimental animals. |
| priorityDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 310.